Chemical Nature of Amyloid

Slide 1 · Chemical Nature of Amyloid

Proteins, fibrils, precursors and clinicopathologic interpretation

Molecular precursor

Misfolded fibril

Tissue deposit

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Differentiate fibril protein chemistry from common amyloid architecture.

Identify the biochemical precursors of AL, ATTR, and AA deposits.

Recognize Aβ, Aβ₂-microglobulin, and prion-associated amyloid examples.

Explain why amyloid detection and biochemical typing are separate steps.

Slide 3 · Amyloid is a chemically heterogeneous deposit

Amyloid is not a single biochemical substance.

More than 40 different proteins can form amyloid.

Histologic similarity reflects a shared fibrillar organization, not identical precursors.

AL

Ig light-chain products

ATTR

Transthyretin

AA

Serum amyloid A–derived

Schematic

Different proteins can converge on a common amyloid morphology.

Slide 4 · Amyloidosis is a family of deposition disorders

Amyloidogenic proteins form insoluble fibrils.

Fibrils accumulate predominantly in extracellular tissues.

Progressive deposits distort tissue architecture and impair function.

Amyloidogenic protein

Fibrils

Extracellular deposits

Shared endpoint across multiple diseases

Schematic

Chemical identity and affected organ together shape disease.

Slide 5 · Microscopic similarity does not imply chemical identity

AL, ATTR, AA, and less common proteins may look alike in routine sections.

The precursor protein supplies the biochemical name of the fibril type.

Typing is essential to distinguish biologically different disorders.

Common morphology

Distinct chemistry

Extracellular hyaline deposits

Different fibril proteins and precursors

Schematic

Appearance identifies amyloid; Chemistry identifies its type.

Slide 6 · The deposit has a fibrillar and a nonfibrillar fraction

Approximately 95% comprises fibril proteins.

The remaining approximately 5% includes serum amyloid P and other glycoproteins.

The fibril protein defines the biochemical amyloid type.

Approximate amyloid deposit composition

~95% fibril proteins

~5%

SAP and other glycoproteins

Schematic

Do not confuse an associated deposit protein with the fibril precursor.

Slide 7 · Serum amyloid P is a deposit-associated component

Serum amyloid P contributes to the nonfibrillar portion of deposits.

It is present alongside different amyloid fibril types.

It does not mean that all amyloid fibrils derive from serum amyloid P.

Amyloid fibril

Serum amyloid P

Proteoglycans

Schematic

SAP is a shared component; AL, ATTR, and AA are different fibril proteins.

Slide 8 · Amyloid interacts with extracellular matrix molecules

Deposits bind proteoglycans and glycosaminoglycans.

Examples include heparan sulfate and dermatan sulfate.

Associated molecules help explain the shared staining behavior.

Amyloid fibrils

Heparan sulfate

Dermatan sulfate

Serum amyloid P

Schematic

An amyloid deposit contains more than the protein making its fibrils.

Slide 9 · The term amyloid does not mean starch

The original name reflected staining features reminiscent of amylose.

Charged sugar-containing molecules contributed to the historical impression.

Amyloid fibrils are aggregated proteins—not starch deposits.

Historical label

Chemical reality

Resembled amylose in staining

Protein-rich extracellular fibrils

Schematic

The name is historical; The material is predominantly protein.

Slide 10 · Amyloid fibrils share a nonbranching ultrastructure

Electron microscopy reveals continuous, nonbranching fibrils.

The architecture is common across multiple chemical amyloid types.

This shared geometry helps explain their common tissue appearance.

Continuous, parallel nonbranching fibrils

Schematic

The fibril shape is a structural signature—not a protein-type label.

Slide 11 · The fibril diameter is approximately 8–10 nm

Amyloid fibrils as roughly 8–10 nm in diameter.

This is an electron-microscopic scale, not resolvable as individual fibrils by light microscopy.

The dimension describes the fibrils, not the extent of a tissue deposit.

Continuous, parallel nonbranching fibrils

Schematic

Never interpret a low-power H&E deposit as a single 8–10 nm fibril.

Slide 12 · β-pleated structure is the organizing motif

Amyloid fibrils contain β-pleated structural elements.

Protofilaments are arranged into stacked molecular assemblies.

Side-chain interactions help bind these arrangements together.

β-pleated sheets → aligned protofilaments

Schematic

The common molecular packing underlies shared staining properties.

Slide 13 · Protofilaments organize into mature fibrils

A protofilament is part of a higher-order fibrillar structure.

Repeated β-pleated molecular units assemble into organized fibers.

The resulting amyloid fibril is insoluble and tends to persist in tissues.

β-pleated units

Protofilaments

Amyloid fibril

Schematic

Protein source differs; Hierarchical fibril assembly is shared.

Slide 14 · Side-chain interactions stabilize fibrillar packing

Protofilament associations involving side chains.

Different amino-acid sequences can adopt the same overall fibrillar architecture.

Common conformation should not be mistaken for a common sequence.

β-pleated sheets → aligned protofilaments

Schematic

Architecture is conserved even when the precursor protein changes.

Slide 15 · Conformation connects chemistry to Congo red

Congo red staining is characteristic of the amyloid fibril arrangement.

The structural feature is shared across chemically distinct amyloid types.

Therefore Congo red indicates amyloid but does not define AL, ATTR, or AA.

β-sheet packing

Congo red binding

Amyloid detection

Schematic

A structural stain is not a protein-typing assay.

Slide 16 · Routine H&E shows amorphous extracellular material

Amyloid appears as an amorphous, eosinophilic, hyaline extracellular substance.

Collagen and fibrin can create superficially similar appearances.

A specific histochemical assessment is therefore useful.

Cell

Amyloid deposit

Cell

Schematic

H&E raises suspicion; Morphology alone is not chemically specific.

Slide 17 · Congo red gives deposits a pink–red appearance

In ordinary illumination, Congo red stains amyloid deposits pink or red.

The stain is used after morphologic recognition of an extracellular deposit.

Interpretation also requires appropriate examination under polarized light.

H&E

Congo red

Eosinophilic, hyaline

Red/pink deposits

Polarizing microscopy assesses birefringence

Schematic

Color under ordinary light is not the whole diagnostic signature.

Slide 18 · Polarized light adds the characteristic birefringence

Congo red–stained amyloid shows characteristic birefringence with polarization.

This feature is more distinctive than pink-red staining alone.

The result establishes amyloid deposits without specifying fibril composition.

Extracellular deposit

Congo red + birefringence

Identify fibril type

Schematic

Detection and chemical identification answer separate questions.

Slide 19 · A positive amyloid stain cannot distinguish its precursor

AL, ATTR, and AA share key structural staining features.

A tissue deposit therefore requires contextual or specific protein typing.

Never infer the amyloid class merely from its Congo red pattern.

Detection

Classification

Amyloid architecture

Fibril protein origin

Schematic

Conformation is common; Precursor identity is not.

Slide 20 · The biochemical name points to the fibril protein

AL denotes an immunoglobulin light-chain–derived fibril.

ATTR denotes transthyretin-derived amyloid.

AA denotes a product derived from serum amyloid A.

AL

Ig light chain

ATTR

Transthyretin

AA

SAA

Schematic

Start each amyloid mechanism by identifying its precursor.

Slide 21 · Three common amyloid types have different origins

AL originates from monoclonal plasma-cell light chains.

ATTR originates from transthyretin, in wild-type or variant forms.

AA originates from liver-produced serum amyloid A after proteolysis.

AL

Plasma-cell product

ATTR

Circulating TTR

AA

Hepatic acute-phase protein

Schematic

The dominant fibril protein is also a clue to pathogenesis.

Slide 22 · Fibril type and precursor are not interchangeable

A circulating precursor may be processed before becoming a fibril.

AL can contain intact light chains or amino-terminal fragments.

AA is proteolytically generated from a larger SAA molecule.

AL

Intact chains and/or fragments

AA

Derived by SAA cleavage

ATTR

Composed of TTR

Schematic

Name the final fibril protein and the source precursor precisely.

Slide 23 · AL means amyloid light chain

The precursor is an immunoglobulin light chain secreted by a clonal plasma-cell population.

AL fibrils can contain entire light chains, fragments, or both.

The designation concerns the fibril protein, not the site of deposition.

Free Ig light chain

AL fibril protein

Schematic

AL chemistry connects tissue amyloid to monoclonal immunoglobulin production.

Slide 24 · Complete immunoglobulin light chains can form AL

Not every AL fibril consists exclusively of a small peptide fragment.

Robbins explicitly includes complete light chains in AL deposits.

The common category is origin from the Ig light-chain polypeptide.

Complete chain

Fragment

Full light-chain polypeptide

Amino-terminal-derived segment

Schematic

AL is a biochemical family rather than a single fixed fragment.

Slide 25 · Amino-terminal fragments also contribute to AL

AL amyloid may contain amino-terminal portions of light chains.

A deposit can contain both whole-chain and fragmented light-chain material.

Proteolytic history is therefore relevant to deposit composition.

Ig light chain

Fragment(s)

AL fibrils

Schematic

Do not define AL as exclusively intact light chains.

Slide 26 · Lambda light chains predominate among analyzed AL

Most characterized AL proteins are λ light-chain–derived.

κ light chains or their fragments can also form amyloid.

Light-chain class alone does not establish fibril formation in an individual.

λ light chain

κ light chain

More frequent in reported AL samples

Also capable of forming AL

Schematic

Both λ and κ can be amyloidogenic; λ predominance is not exclusivity.

Slide 27 · The AL precursor comes from a monoclonal clone

A monoclonal plasma-cell population secretes free Ig light chains.

A subset of the secreted molecules has amyloid-forming potential.

Deposits may be associated with plasma-cell neoplasms.

Plasma-cell clone

Free light chains

AL fibrils

Schematic

Link the fibril protein to its producing cell population.

Slide 28 · AL deposition links protein production to tissue damage

A precursor is generated by abnormal plasma-cell production.

Amyloidogenic light chains aggregate and deposit extracellularly.

The tissue deposit is the mechanism of organ injury in amyloidosis.

Light-chain source

Aggregation

Tissue deposition

Schematic

The source clone and the affected tissue may be anatomically separate.

Slide 29 · AL is not synonymous with multiple myeloma

Robbins relates AL to certain plasma-cell tumors and monoclonal populations.

The molecular definition is light-chain composition of the fibril.

An AL diagnosis requires attention to the protein source, not a tumor label alone.

Amyloid protein

Associated disorder

AL light-chain fibril

Monoclonal plasma-cell disease

Schematic

Distinguish amyloid type from its associated hematologic disorder.

Slide 30 · Transthyretin is the precursor of ATTR

ATTR fibrils are composed of transthyretin (TTR).

TTR is a circulating plasma protein.

Its transport roles for thyroxine and retinol.

Circulating transthyretin

ATTR fibrils

Schematic

A normal physiologic transport protein can become amyloidogenic.

Slide 31 · Wild-type transthyretin can aggregate

ATTRwt denotes deposits produced from unmutated or wild-type TTR.

Aging favors the amyloidogenic behavior.

This form commonly involves the heart.

Wild-type TTR

Age-associated aggregation

ATTRwt deposits

Schematic

A genetic TTR variant is not required for all ATTR amyloid.

Slide 32 · ATTRwt has a characteristic cardiac association

The heart as the usual site of ATTRwt deposition.

It particularly describes older men, commonly above age 70.

Organ distribution provides a clinical clue, not a substitute for amyloid typing.

Wild-type TTR

Cardiac deposition

Older adults

Systemic amyloid

Schematic

Consider precursor and organ together; Neither alone confirms the type.

Slide 33 · Variant transthyretin forms ATTRv

ATTRv arises from variant forms of transthyretin.

Variant TTR can misfold and form extracellular fibrils.

This is chemically distinct from AL and AA despite shared morphology.

Variant TTR

Misfolding

ATTRv fibrils

Schematic

The altered molecule remains transthyretin-derived amyloid.

Slide 34 · ATTRv may involve nerves as well as heart

Heart, peripheral nerves, and additional tissues as sites.

Different variant TTR proteins can show different organ distributions.

Distribution cannot by itself specify the exact variant.

Peripheral nerve

Heart

Other tissues

Variable distribution

Schematic

Variant protein identity and tissue tropism are related but not identical.

Slide 35 · Wild-type and variant ATTR share the same protein family

Both classes deposit transthyretin-derived fibrils.

ATTRwt refers to aggregation of wild-type protein.

ATTRv refers to amyloid associated with altered TTR sequence.

ATTRwt

ATTRv

Wild-type TTR; Often cardiac

Variant TTR; Heart and/or nerves

Schematic

The wt/v distinction describes precursor status within ATTR.

Slide 36 · Aging and molecular variation are distinct routes

Normal proteins may become amyloidogenic in an age-associated setting.

Variant proteins can have enhanced tendency toward abnormal folding.

Both routes converge on extracellular fibrils.

TTR substrate

Misfolding

ATTR fibrils

Schematic

Multiple upstream causes can produce the same structural endpoint.

Slide 37 · AA is a processed product of serum amyloid A

AA fibril protein is generated from a larger precursor, SAA.

SAA is synthesized by hepatocytes and released into blood.

Proteolysis links the circulating precursor to the deposited fibril component.

Liver SAA

Proteolysis

AA fibrils

Schematic

The deposited AA protein is not equivalent to the intact SAA precursor.

Slide 38 · SAA is produced in the liver

The precursor protein enters the circulation after hepatic synthesis.

This explains how a protein made at one site can deposit in distant organs.

A systemic precursor should not be confused with localized tissue production.

Hepatic SAA production

Circulating precursor

Schematic

Hepatic origin is a defining biochemical feature of AA.

Slide 39 · Circulating SAA associates with HDL

The source states that SAA circulates bound to high-density lipoproteins.

The lipoprotein association concerns precursor transport in plasma.

AA deposits ultimately contain fibrils derived from this precursor.

Blood

Tissue

SAA associated with HDL

AA-derived extracellular fibrils

Schematic

Separate the circulating molecular complex from insoluble tissue fibrils.

Slide 40 · SAA is an acute-phase reactant

Inflammatory states increase SAA production.

Raised SAA reflects the hepatic acute-phase response.

Sustained precursor exposure is associated with AA amyloidosis.

Inflammation

Increased SAA

AA substrate

Schematic

The inflammatory context explains the source of abundant substrate.

Slide 41 · Proteolysis converts SAA into AA components

The final AA fibril protein is derived from a larger SAA polypeptide.

Proteolytic processing generates the smaller amyloid-associated product.

Thus precursor processing is integral to AA nomenclature.

Full SAA

Proteolytic cleavage

AA protein

Schematic

AA names the deposited amyloidogenic product; SAA names its precursor.

Slide 42 · Chronic inflammation explains AA association

Inflammation increases liver synthesis of SAA.

Long-standing inflammatory conditions can maintain precursor abundance.

This supplies a biochemical connection to AA fibril accumulation.

Chronic inflammation

SAA synthesis

AA deposition

Schematic

In AA amyloidosis the clinical setting and chemical precursor are linked.

Slide 43 · AL and AA differ in the source of their precursor

AL involves an Ig light chain produced by monoclonal plasma cells.

AA involves hepatic SAA increased by an inflammatory response.

Both precursors can ultimately yield extracellular amyloid fibrils.

AL

AA

Plasma-cell Ig light chains

Hepatic acute-phase SAA

Schematic

Different upstream biology; Convergent fibrillar phenotype.

Slide 44 · Three major precursors follow distinct pathways

AL: Monoclonal free light-chain production.

ATTR: Wild-type or variant transthyretin aggregation.

AA: Increased SAA and generation of AA fragments.

AL

Clonal Ig light chains

ATTR

TTR misfolding

AA

SAA proteolysis

Schematic

Precursor identification is the organizing principle of amyloid chemistry.

Slide 45 · Aβ is derived from amyloid precursor protein

Amyloid-β is formed by proteolysis of amyloid precursor protein (APP).

APP is a larger transmembrane glycoprotein.

Aβ represents a distinct biochemical amyloid species.

Membrane APP

Proteolysis

Aβ peptide

Schematic

Aβ is not another name for AL, ATTR, or AA.

Slide 46 · Aβ forms the core of Alzheimer plaques

The Aβ protein forms a central component of cerebral plaques in Alzheimer disease.

This is a tissue-specific association given by the source.

The biochemical identity differs from circulating light chains or TTR.

APP in neural tissue

Aβ in cerebral plaques

Schematic

Brain amyloid can arise from local processing of a membrane precursor.

Slide 47 · Aβ also deposits in cerebral blood vessel walls

Aβ deposits in walls of cerebral vessels.

Plaque and vessel-wall deposition are distinct anatomical patterns.

Both can involve the same biochemical Aβ protein species.

Plaque core

Vessel wall

Cerebral parenchymal setting

Cerebral vascular setting

Schematic

One fibril protein may occur in more than one cerebral compartment.

Slide 48 · β₂-microglobulin is an MHC class I component

β₂-microglobulin normally associates with MHC class I molecules.

It is also a normal circulating plasma protein.

Under particular clinical conditions it can become the amyloid fibril protein.

β₂-microglobulin

Aβ₂m fibrils

Schematic

A physiologic host protein can become an amyloid precursor.

Slide 49 · Long-term dialysis is associated with Aβ₂m

β₂-microglobulin amyloid with long-term hemodialysis.

Deposits appear in or around joints and soft tissues.

This is a distinct precursor from Aβ in the central nervous system.

β₂-microglobulin

Long-term dialysis

Joint/soft-tissue amyloid

Schematic

Similar abbreviations must not obscure unrelated proteins.

Slide 50 · Prion proteins can rarely form amyloid deposits

In a minority of CNS prion-disease cases, misfolded prion proteins aggregate extracellularly.

The aggregates can acquire amyloid-like structural and staining properties.

This is a special, less common amyloid example.

Misfolded prion protein

Extracellular aggregate

Amyloid features

Schematic

Amyloid conformation can arise from another structurally distinct protein.

Slide 51 · Less common proteins broaden amyloid chemistry

Aβ is associated with Alzheimer plaques and cerebrovascular deposits.

β₂-microglobulin is associated with long-term hemodialysis.

Some misfolded prion proteins can acquire amyloid characteristics.

Aβ

APP-derived peptide

Aβ₂m

MHC I–associated protein

Prion

Misfolded prion protein

Schematic

Amyloid represents a material class formed by multiple proteins.

Slide 52 · Identical staining may conceal different diseases

Congo red detects shared fibril architecture.

Amyloid chemistry separates plasma-cell, TTR, inflammatory, cerebral, and dialysis-related pathways.

Clinicopathologic interpretation therefore needs both morphology and protein identity.

Extracellular deposit

Congo red + birefringence

Identify fibril type

Schematic

Avoid a one-to-one mapping from staining phenotype to disease category.

Slide 53 · Localized and systemic deposits reflect precursor context

Local deposition from deposits occurring away from protein production.

Circulating precursors can support systemic involvement.

Local precursors can be associated with restricted deposition patterns.

Localized

Systemic

At production site

Away from production site

Schematic

Chemical source and distribution are linked concepts, not identical labels.

Slide 54 · Protein folding is the shared final route

Amyloidogenic proteins misfold and form oligomers.

Oligomers can progress to larger aggregates and insoluble fibrils.

The precursor determines which amyloid protein reaches this pathway.

Misfolded monomer

Oligomer

Fibrils

Deposit

Schematic

Shared structural pathway; Distinct initial biochemical input.

Slide 55 · Chemical typing changes the etiologic question

If fibrils are AL, investigate the immunoglobulin light-chain source.

If fibrils are ATTR, consider wild-type versus variant TTR.

If fibrils are AA, examine the inflammatory/SAA pathway.

AL

Monoclonal plasma cells?

ATTR

TTR wild-type or variant?

AA

Sustained inflammation?

Schematic

The type guides the next clinicopathologic question.

Slide 56 · Do not identify AL simply from birefringence

An extracellular Congo red–positive deposit suggests amyloid.

The structural stain does not specify the light-chain composition.

AL requires evidence that the deposited fibril protein is light-chain derived.

Extracellular deposit

Congo red + birefringence

Identify fibril type

Schematic

Detection is necessary but insufficient for biochemical typing.

Slide 57 · Clinical exercise: Monoclonal light-chain production

A patient has extracellular amyloid and a monoclonal plasma-cell population.

Free Ig light chains are the candidate fibril precursor.

Which biochemical amyloid type does this suggest, and why?

Identify the precursor

Ig light chain → AL

Schematic

Expected reasoning: Precursor origin → AL.

Slide 58 · Clinical exercise: Cardiac amyloid in later life

An older man has a cardiac amyloid deposit.

Wild-type transthyretin is a recognized substrate in this setting.

Which fibril type should be considered, without assuming it is proven?

Identify the precursor

Wild-type TTR → ATTRwt

Schematic

Expected reasoning: Wild-type TTR → possible ATTRwt.

Slide 59 · Clinical exercise: Long-standing inflammation

A patient with chronic inflammatory disease develops tissue amyloid.

The liver produces increased SAA during the acute-phase response.

Which proteolytic product forms the relevant fibrils?

Identify the precursor

SAA → AA

Schematic

Expected reasoning: SAA processing → AA.

Slide 60 · Clinical exercise: Distinct cerebral deposits

Amyloid occurs in an Alzheimer-type cerebral plaque.

The implicated peptide is derived from a transmembrane precursor.

Name the peptide and its larger source protein.

Identify the precursor

APP → Aβ

Schematic

Expected reasoning: Aβ is produced from APP.

Slide 61 · Clinical exercise: Amyloid around joints

A long-term hemodialysis patient has periarticular amyloid.

The precursor is normally part of MHC class I complexes.

Which fibril protein does this point toward?

Identify the precursor

β₂-microglobulin

Schematic

Expected reasoning: β₂-microglobulin → Aβ₂m.

Slide 62 · Chemical identity and organ site: A reasoning grid

AL: Immunoglobulin-derived, often associated with plasma-cell proliferation.

ATTR: TTR-derived, particularly relevant to cardiac and neural deposits.

AA: SAA-derived, linked to inflammatory states.

Other types: Aβ, Aβ₂m, and occasional prion amyloid.

Source

Identify producing system

Tissue

Recognize distribution

Fibril

Determine biochemical type

Schematic

Map tissue findings to possible precursors—not to a single automatic diagnosis.

Slide 63 · Five biochemical distinctions to retain

Amyloid deposits have common β-pleated fibril organization but many protein origins.

Approximately 95% of deposit mass is fibril protein.

AL, ATTR, and AA have distinct precursor molecules.

Aβ and Aβ₂m are different proteins despite similar abbreviations.

Conformation

Protein fraction

AL / ATTR / AA

Other precursors

Schematic

Chemical type should be specified separately from the demonstration of amyloid.

Slide 64 · Integrating structural and chemical evidence

Electron-microscopic structure explains similar Congo red behavior.

Chemical precursor explains differences among amyloid diseases.

Clinical context narrows hypotheses but does not replace typing.

Protein precursor

β-rich fibril

Tissue amyloid

Schematic

Best mental model: Shared fibril architecture + distinct precursor protein.

Slide 65 · Selected source and interpretation notes

Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th edition (2026), section: Amyloidosis.

Primary section: Chemical Nature of Amyloid; contextual sections: Properties and Physical Nature of Amyloid.

Adjacent topics provide limited context on pathogenesis, AL, ATTR, and AA; no outside clinical criteria were introduced.

All visuals are editable teaching schematics; none represents an authentic microscopic specimen.